Iatrogenic steroidinduced myopathy, first described by dubois in 1958, is well recognized in its chronic form but considerably less in the acute, early onset variant. It may result from excessive endogenous cushings syndrome or exogenous steroids. Steroid myopathy is usually an insidious disease process that causes weakness mainly to the proximal muscles of the upper and lower limbs and to the neck flexors. Cushing originally described it in 1932, and muller and kugelberg first studied it systemically in 1959. Myopathy can occur with any of the glucocorticoid preparations. Two different clinical patterns of steroidinduced muscular changes are known. In acute myopathy and atrophy after short term treatment with high doses of steroids, generalized muscle atrophy and rhabdomyolysis occur, including the respiratory muscles. Nearly 60% of patients with cushings syndrome have muscle weakness. The mme and fim were evaluated by a physical therapist on patients diagnosed with steroidinduced. Glucocorticoidinduced myopathy, characterized by muscle weakness without pain, fatigue and atrophy, is an adverse effect of glucocorticoid use and is the most common type of druginduced myopathy. Steroidinduced myopathy is a complication of highdose steroid use. This muscle disturbance has a frequency of 60%, and it has been most often associated with fluorinated glucocorticoid preparations.
1372 681 1004 249 37 308 1541 403 1212 59 471 118 1171 1124 1607 404 85 1608 481 93 302 1099 509 45 151 785 977 1425 79 1111 621 622 1256